FIGURE 5 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
Year: 2023
Type: other
Abstract: Prediction of drug responses in palbociclib-resistant cells. For −DOX cells (A) and for +DOX cells (B) are the estimated drug response curves of the effect of palbociclib on G1–S transition rate. The blue (−DOX) and red (+DOX) curves are given by the estimated model parameter of the palbociclib-sensitive MCF7 cell line. The green (−DOX) and orange (+DOX) curves are given by the estimated model parameter of the palbociclib-resistant MCF7 cell line. The gray shaded area corresponds to the 95% credible interval of the posterior predictive values. C–F show the box plots for the number of cells at day 100 given by the in silico trial predictions of multiple palbociclib treatment administration schedules in combination with fulvestrant. The p-values were computed using the Wilcoxon test. C and D are −DOX/+DOX cells of the palbociclib-sensitive MCF7 cell line. E and F are −DOX/+DOX cells of the palbociclib-resistant MCF7 cell line (+PR).
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4388735010